【正文】 y0C3F6IaLdPgSjVnYq!t*wA1D4G8JbMeQhTl WoZr%u( x+B2E6H9KcOfRiU mXp!samp。w)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiTl Xos%v( y0B3E6I9LdOgRjVmYp!tamp。v)z0C 3F7IaMdPgSkVnYq$t*xA1D 5G8JbNeQiTl Wor %u( y+B2E6H9LcOfRj U mXp!samp。v)z0C3F7IaMdPgSkVnYq$t*xA1D5G8JbN eQiTl Wor%u(3F7IaLdPgSjVnYq$t*wA1D 4G8JbMeQhTl WoZr %u( x+ B2E6H9KcOfR iU mXp!samp。w) z1C4G7JaMePhSkWnZr$u*x+A2D 5H8KcNfQiUl Xos%v) y0B3F6I9LdOgSjVmYq!tamp。w)z0C4F7JaMdPhSkVnZq$u*xA2D5G8KbNfQi TlXor %v( y0B3E6I9LcOgRjVmYp!tamp。w)z0C4F7JaM dPhSkVnZq$u*xA2D5G8KbNfQiTlXor%v( y0B3E6I9LcOgRjU mYp!tamp。wz1C4G7JbMePhTkWnZr$u( x+ A2E5H 8KcNfR iUlXps%v) y0B3F6IaLdOgSjVmYq!t*wz1D4G7JbMeQhTkWoZr$u( x+B2E5H9KcNfRiU mXpsamp。v)z0C3F7IaMdPgSkVnYq$t*xA1D5G8JbNeQi Tl Wor %u( y+ B3E6H 9LcOfRjU mYp!samp。 OR revascularization Followup: Until 50 conventional pts CV event 11 yrs post DCCT。 I G TI G TI F G 3039 4049 5059 6069 7079 8089 Prevalence (%) of IGT but not IFG increases with age in DECODE population The DECODE group, Diabetes Care 2022。2小時(shí)糖耐量試驗(yàn)的臨床意義 Finnish Academy Research Fellow 芬蘭赫爾辛基大學(xué)及 國立公共衛(wèi)生研究院 北大糖尿病論壇 2022年 5 月 12日， 北京 喬青 MD, 糖尿病診斷試驗(yàn) :歷史回顧 糖尿病 Jacobsen A. Biochem Z 51:443, 1913 Normal Glucose Homeostasis Daytime Profile (N=12, health。 26: 6169. Hazards ratio for allcause mortality in subjects without prior history of diabetes Adj. for age, cohorts, sex, chol, BMI, SBP, smoking 2,011,491,77 ? – ? – Fasting plasma glucose (mmol/l) Hazard ratio Adapted from DECODE Study Group, Lancet 1999。 17 yrs altogether GHb Results: DCCT End EDIC End Intensive () () Conventional () () Intensive Insulin Rx amp。w) z0C4F7JaMdPhSkVnZq$t*xA2D5G8KbNeQiTlXor%v( y+B3E6I9LcOgRjU mYp!tamp。v) y0C3F7IaLdPgSjVnYq$t*wA1D4G8JbNeQhTlWoZr%u( x+ B2E6H 9KcOfRiU mXp!samp。w)z1C 4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQi UlXos%v( y0B3F6I9LdOgRjVmYq!tamp。w)z1C4G7JaMePhSkWnZr $u*x+ A2D5H 8KbNfQiUlXos%v( y0B3F6I9LdOgRjVmYq!tamp。wz1D4G7JbMePhTkWnZr$u( 。v) y0C3F7IaLdPgSjVnYq$t*wA1D4G8JbNeQhTl WoZr%u( y+B2E6H9KcOfRiU mXp!samp。v) y0C3F6IaLdPgSjVnYq!t*wA1D4G8JbMeQhTl WoZr%u( x+B2E6H9KcOfRiU mXp!samp。w)z0C4F7IaMdPhSkVnZq$t*xA2D5G8KbN eQiTlXor%v( y+B3E6I9LcOgRjU mYp!tamp。wz1C4G7JaMePhTkWnZr$u*x+A2E5H8KcN fQiUlXps%v) y0B3F6IaLdOgSjVmYq!t*wz1D4G7JbMeQhTkWoZr$u( x+A2E5H9KcNfRiUl Xpsamp。353:2643 Primary CV Composite RRR= 42% (963) RRR after adj. for updated GHb until end of DCCT (or CV event during DCCT): 16% (64 – 57) P= Intensive Insulin Rx amp。 26: 688696 010002022300040001 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1701234513 .02 h o u r pla s ma g luc o s e ( mm o l/ l)CVD mortality by 2hour plasma glucose Frequency Hazard ratio DECODE, Diabetes Care 26: 688696 CVD mortality by fasting plasma glucose 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 170123450202240006000800010000 8 . 5 4 . 0F a s t ing pla s ma glu c o s e ( mm o l/ l)Frequency Hazard ratio DECODE, Diabetes Care 26: 688696 Hazard ratio for mortality by FPG categories, th